Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01223027
First received: September 30, 2010
Last updated: November 5, 2015
Last verified: November 2015
  Purpose
This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.

Condition Intervention Phase
Metastatic Renal Cell Carcinoma
Drug: Dovitinib
Drug: Sorafenib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Progression Free Survival (PFS) Per Independent Central Radiology Review [ Time Frame: Until disease progression or discontinuation of treatment due to unacceptable toxicity up to 30-Jun-2014 (discontinuation) ] [ Designated as safety issue: No ]
    Assessed according to RECIST 1.1. PFS was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause. If a patient had not progressed or died, on the date of the analysis cut-off or when he/she received any further anti-neoplastic therapy, PFS was censored on the date of last tumor assessment before the cutoff date or the anti-neoplastic therapy date. The distribution of PFS was estimated using the Kaplan-Meier method. The median PFS along with 95% confidence intervals was presented by treatment group.


Secondary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: until at least 386 deaths are documented in the clinical database. ] [ Designated as safety issue: No ]
    Overall survival (OS) was the key secondary endpoint and was defined as the time from date of randomization to the date of death due to any cause. If a patient was not known to have died, survival was censored on the date of last contact.

  • Progression Free Survival (PFS) Per Investigator's Radiology Review [ Time Frame: Until disease progression or discontinuation of treatment due to unacceptable toxicity ] [ Designated as safety issue: No ]
    PFS was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause. The primary analysis for PFS (based on central review) was also to be repeated on FAS considering the Investigator assessments and using the same analytical conventions as the primary analysis.

  • Percentage of Participants With Overall Response Rate (ORR) by Central Radiology Review [ Time Frame: Until disease progression or discontinuation of treatment due to unacceptable toxicity ] [ Designated as safety issue: No ]
    Overall response rate (ORR) was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR). Best overall esponse (BOR) for each patient was determined from the sequence of overall (lesion) responses according to the following rules: CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required. CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required. SD = at least one SD assessment (or better) > 6 weeks after randomization (and not qualifying for CR or PR). PD = progression ≤ 17 weeks after randomization (and not qualifying for CR, PR or SD).

  • Time to Definitive Worsening of Karnofsky Performance Status (KPS) [ Time Frame: from date of randomization to the date of definitive worsening of KPS or to the date of death whichever occurred earlier ] [ Designated as safety issue: No ]
    Time to definitive worsening of Karnofsky performance status (KPS) was defined as the time from date of randomization to the date of definitive worsening of KPS or to the date of death whichever occurred earlier. Definitive worsening was defined as a definitive decrease in performance status by at least one Karnofsky category (i.e. at least 10 points less) compared to Baseline. Worsening was considered definitive if no later increase above the defined threshold was observed within the course of the study. A single measure reporting a decrease in Karnofsky performance status was sufficient to consider it as definitive only if it was the last one available for this patient. Time to definitive worsening of KPS was analyzed at the time of the final analysis for PFS.

  • Patient-reported Outcomes (PROs): Time to Deterioration of Functional Assessment of Cancer Therapy-Kidney Symptom Index, Disease Related Symptoms (FKSI-DRS) by at Least 2 Scores [ Time Frame: from date of randomization, at least 2 score units ] [ Designated as safety issue: No ]
    The Kidney Cancer Symptom Index - Disease Related Symptoms (FKSI-DRS) is a validated symptom scale used in studies of patients with kidney cancer. It includes 9-items that assess pain, bone pain, fatigue, lack of energy, shortness of breath, fevers, weight loss, coughing, and blood in urine and responses to each question are answered on a 5-point Likert-type scale ranging from 0 to 4 (e.g., 0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). FKSI-DRS scores range from 0 to 36, where higher scores correspond to better outcomes (eg, fewer symptoms).

  • Patient-reported Outcomes (PROs): Time to Definitive Deterioration of the Physical Functioning (PF) Scale of EORTC QLQ-C30 by at Least 10% [ Time Frame: from date of randomization ] [ Designated as safety issue: No ]
    The EORTC QLQ-C30 contains 30 items and is composed of both multi-item scales and single-item measures. These include five functional scales (physical, role, emotional, social and cognitive functioning), three symptom scales (fatigue, pain, nausea, and vomiting), a global health status/QoL scale, and six single items (dyspnea, diarrhea, constipation, anorexia, insomnia and financial impact). Each of the multiitem scales includes a different set of items - no item occurs in more than one scale. Each item in the EORTC QLQ-C30 has 4 response categories (1=Not at all, 2= A little, 3= Quite a bit, 4= Very much) with the higher number representing a worse outcome.

  • Patient-reported Outcomes (PROs): Time to Definitive Deterioration of the Quality of Life (QoL) Scale Scores of EORTC QLQ-C30 by at Least 10% [ Time Frame: from date of randomization ] [ Designated as safety issue: No ]
    The EORTC QLQ-C30 contains 30 items and is composed of both multi-item scales and single-item measures. These include five functional scales (physical, role, emotional, social and cognitive functioning), three symptom scales (fatigue, pain, nausea, and vomiting), a global health status/QoL scale, and six single items (dyspnea, diarrhea, constipation, anorexia, insomnia and financial impact). Each of the multiitem scales includes a different set of items - no item occurs in more than one scale. Each item in the EORTC QLQ-C30 has 4 response categories (1=Not at all, 2= A little, 3= Quite a bit, 4= Very much) with the higher number representing a worse outcome.

  • Pre-dose Concentration in Plasma in Dovitinib [ Time Frame: Week 2 Day 5, Week 4 Day 5, Week 6 Day 5 ] [ Designated as safety issue: No ]
    Predose concentrations of dovitinib were summarized by visit using PAS. All concentration data was listed by patient and time point using FAS. Mean pre-dose concentrations along with standard deviation (SD) was plotted over time if appropriate.


Enrollment: 564
Study Start Date: March 2011
Study Completion Date: June 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dovitinib + best supportive care (BSC)
Patients randomized to the dovitinib treatment arm received 500 mg of dovitinib orally on 5 days on/2 days off dosing schedule.
Drug: Dovitinib
Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
Other Name: TKI258
Active Comparator: Sorafenib + BSC
Patients in the sorafenib control arm received400 mg of sorafenib (2 x 200 mg tablets) orally taken twice daily.
Drug: Sorafenib
Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with metastatic renal cell carcinoma (mRCC) with histological or cytological confirmation of clear cell carcinoma or a component of clear cell
  • Patients must have received one and only one prior VEGF-targeted therapy and one and only one prior mTOR inhibitor therapy in the metastatic setting. One VEGF targeted therapy (e.g. sunitinib, or pazopanib, or axitinib, or tivozanib or bevacizumab) and one prior mTOR inhibitor therapy (everolimus, or temsirolimus or ridaforolimus)
  • Prior cytokines therapy and prior vaccines in the adjuvant setting is permitted.
  • Patients must have had disease progression on or within 6 months of stopping the last therapy.
  • Patients must have at least one measurable lesion at baseline (by RECIST Criteria Guidelines v1.1) assessed by Computer Tomography (CT) Scan or Magnetic Resonance Imaging (MRI).
  • Karnofsky performance status ≥ 70%
  • Patients must have the following laboratory values:

    • Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
    • Platelets ≥ 100 x 109/L
    • Hemoglobin (Hgb) > 9 g/dL
    • Serum total bilirubin: ≤ 1.5 x ULN
    • ALT and AST ≤ 3.0 x ULN (Patients with known liver metastases: AST and ALT ≤ 5.0 x ULN)
    • Serum creatinine ≤ 1.5 x ULN

Exclusion Criteria:

  • Patients who have previously received sorafenib therapy in the neoadjuvant, adjuvant or metastatic setting.
  • Patients who have previously received Dovitinib or brivanib in the neoadjuvant, adjuvant or metastatic setting.
  • Patients with brain metastases. Radiological imaging (e.g. CT or MRI scan) of the brain is required at screening/baseline
  • Patients with another primary malignancy within 3 years prior to starting study treatment, with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma or non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix
  • Patients who have received the last administration of an anticancer targeted small molecule therapy ≤ 2 weeks prior to starting study treatment (e.g. sunitinib, pazopanib, axitinib, everolimus, temsirolimus), or who have not recovered from the side effects of such therapy
  • Patients who have received the last administration of nitrosurea or mitomycin-C ≤ 6 weeks prior to starting study treatment, or who have not recovered from the side effects of such therapy
  • Patients who have undergone major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) ≤ 4 weeks prior to starting study treatment or who have not recovered from side effects of such therapy
  • Patients with a history of pulmonary embolism (PE), or untreated deep venous thrombosis (DVT) within the past 6 months
  • Patients with concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01223027

  Hide Study Locations
Locations
United States, Arkansas
Highlands Oncology Group Dept of Highlands Oncology Grp
Fayetteville, Arkansas, United States, 72703
United States, California
University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (5)
La Jolla, California, United States, 92093-0658
University of California at Los Angeles UCLA (4)
Los Angeles, California, United States, 90095
Cedars Sinai Medical Center Cedars Sinai Medical Ctr. (SC)
Los Angeles, California, United States, 90048
Stanford University Medical Center Cancer Clinical Trials Office
Stanford, California, United States, 94304
United States, Colorado
Rocky Mountain Cancer Centers RMCC
Greenwood Village, Colorado, United States
United States, Florida
Florida Cancer Specialists DeptofFloridaCancerSpecialists
Fort Myers, Florida, United States, 33901
United States, Georgia
University Cancer & Blood Center, LLC
Athens, Georgia, United States, 30607
United States, Hawaii
Moanalua Medical Center. Attn: Oncology Dept
Honolulu, Hawaii, United States, 96817
Straub Clinic & Hospital Straub
Honolulu, Hawaii, United States, 96813
United States, Kansas
University of Kansas Cancer Center Univ of KS
Kansas City, Kansas, United States, 66160
United States, Maryland
University of Maryland Medical Center UMMC
Baltimore, Maryland, United States, 21201
United States, Michigan
Karmanos Cancer Institute Dept.of KarmanosCancerInst (5)
Detroit, Michigan, United States, 48201
United States, Minnesota
University of Minnesota Medical Center - Fairview Univ of MN
Minneapolis, Minnesota, United States, 55455
United States, Nevada
Comprehensive Cancer Centers of Nevada CCC of Nevada (1)
Las Vegas, Nevada, United States, 89109
United States, New Jersey
CINJ at Cooper University Hospital Cooper
Voorhees, New Jersey, United States, 08043
United States, New York
Memorial Sloan Kettering Cancer Center Dept. of MSKCC
NY, New York, United States, 90033
SUNY - Upstate Medical University Div. of Hematology-Oncology
Syracuse, New York, United States, 13210
New York Oncology Hematology, P.C. Dept. of New York Oncology. PC
Troy, New York, United States, 12180
United States, Oregon
Willamette Valley Clinical Studies Williamette Valley Cancer
Eugene, Oregon, United States, 97404
United States, Pennsylvania
St. Luke's Hospital and Health Network St Luke's
Bethlehem, Pennsylvania, United States
United States, South Carolina
Medical University of South Carolina -Hollings Cancer Center Med Univ SC
Charleston, South Carolina, United States, 29425
Cancer Centers of the Carolinas CC of C -Eastside
Greenville, South Carolina, United States, 29605
United States, Tennessee
Sarah Cannon Research Institute SC - 3
Chattanooga, Tennessee, United States, 37404
The West Clinic
Memphis, Tennessee, United States, 38120
Vanderbilt University Medical Center SC
Nashville, Tennessee, United States, 37232
United States, Texas
Texas Oncology Texas Oncology - Houston
Dallas, Texas, United States, 75251
Texas Oncology Texas Onc - Austin
Dallas, Texas, United States, 75251
Baylor Health Care System/Sammons Cancer Center Dept. of Sammons Cancer (4)
Dallas, Texas, United States, 75246
University of Texas Southwestern Medical Center UTSW
Dallas, Texas, United States, 75390-9034
Deke Slayton Cancer Center Deke Slayton Cancer Center (2)
Webster, Texas, United States, 77598
United States, Utah
Utah Cancer Specialists Dept.of Utah Cancer Spec. (3)
Salt Lake City, Utah, United States, 84106
United States, Virginia
University of Virginia Health Systems Univ Virginia
Charlottesville, Virginia, United States, 22908-0334
United States, Washington
Rockwood Clinic Spokane Location
Spokane, Washington, United States, 99202
Argentina
Novartis Investigative Site
Rosario, Sante Fe, Argentina, S200DSK
Novartis Investigative Site
Buenos Aires, Argentina, C1050AAK
Australia, New South Wales
Novartis Investigative Site
St. Leonards, New South Wales, Australia, 2065
Novartis Investigative Site
Westmead, New South Wales, Australia, 2145
Australia, Queensland
Novartis Investigative Site
South Brisbane, Queensland, Australia, 4101
Australia, South Australia
Novartis Investigative Site
Woodville, South Australia, Australia, 5011
Australia, Victoria
Novartis Investigative Site
Footscray, Victoria, Australia, 3011
Novartis Investigative Site
Heidelberg, Victoria, Australia, 3084
Austria
Novartis Investigative Site
Linz, Austria, A-4020
Novartis Investigative Site
Wien, Austria, 1090
Belgium
Novartis Investigative Site
Bruxelles, Belgium, 1000
Novartis Investigative Site
Bruxelles, Belgium, 1200
Novartis Investigative Site
Gent, Belgium, 9000
Novartis Investigative Site
Leuven, Belgium, 3000
Novartis Investigative Site
Liège, Belgium, 4000
Brazil
Novartis Investigative Site
Porto Alegre, RS, Brazil, 90610-000
Canada, Alberta
Novartis Investigative Site
Calgary, Alberta, Canada, T2N 4N2
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Novartis Investigative Site
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Nova Scotia
Novartis Investigative Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
Novartis Investigative Site
Hamilton, Ontario, Canada, L8N 4A6
Novartis Investigative Site
London, Ontario, Canada, N6A 4L6
Novartis Investigative Site
Ottawa, Ontario, Canada, K1H 8L6
Novartis Investigative Site
Toronto, Ontario, Canada, M4N 3M5
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H2L 4M1
Novartis Investigative Site
Montreal, Quebec, Canada, H2X 1N8
Novartis Investigative Site
Montreal, Quebec, Canada, H3T 1E2
Canada, Saskatchewan
Novartis Investigative Site
Saskatoon, Saskatchewan, Canada, S7N 4H4
Colombia
Novartis Investigative Site
Bogota, Colombia
Czech Republic
Novartis Investigative Site
Brno, Czech Republic, 656 53
Novartis Investigative Site
Olomouc, Czech Republic, 775 20
Novartis Investigative Site
Praha 5, Czech Republic, 150 06
France
Novartis Investigative Site
Besancon Cedex, France, 25030
Novartis Investigative Site
Bordeaux Cedex, France, 33075
Novartis Investigative Site
Caen Cedex, France, 14021
Novartis Investigative Site
Clermont-Ferrand, France, 63011
Novartis Investigative Site
Grenoble, France, 38043
Novartis Investigative Site
Lyon Cedex, France, 69373
Novartis Investigative Site
Marseille, France, 13273
Novartis Investigative Site
Nice Cedex 2, France, 06189
Novartis Investigative Site
Paris, France, 75015
Novartis Investigative Site
Paris Cedex 13, France, 75651
Novartis Investigative Site
Rennes Cedex, France, 35062
Novartis Investigative Site
Saint Priest en Jarez Cedex, France, 42271
Novartis Investigative Site
Saint-Herblain Cédex, France, 44805
Novartis Investigative Site
Strasbourg Cedex, France, F-67098
Novartis Investigative Site
Suresnes, France, 92150
Novartis Investigative Site
Toulouse Cedex 9, France, 31059
Novartis Investigative Site
Vandoeuvre-Les-Nancy Cede, France, 54511
Novartis Investigative Site
Villejuif Cedex, France, 94805
Germany
Novartis Investigative Site
Aschaffenburg, Germany, 63739
Novartis Investigative Site
Berlin, Germany, 10098
Novartis Investigative Site
Chemnitz, Germany, 09119
Novartis Investigative Site
Erlangen, Germany, 91054
Novartis Investigative Site
Greifswald, Germany, 17475
Novartis Investigative Site
Hamburg, Germany, 20246
Novartis Investigative Site
Hannover, Germany, 30625
Novartis Investigative Site
Heidelberg, Germany, 69120
Novartis Investigative Site
Jena, Germany, 07740
Novartis Investigative Site
Leipzig, Germany, 04103
Novartis Investigative Site
Marburg, Germany, 35039
Novartis Investigative Site
Muenster, Germany, 48149
Novartis Investigative Site
München, Germany, 81675
Novartis Investigative Site
Nuernberg, Germany, 90419
Novartis Investigative Site
Ulm, Germany, 89081
Novartis Investigative Site
Weiden, Germany, 92637
Greece
Novartis Investigative Site
Athens, GR, Greece, 115 27
Novartis Investigative Site
Thessaloniki, GR, Greece, 546 45
Novartis Investigative Site
Athens, Greece, 115 28
Hungary
Novartis Investigative Site
Budapest, Hungary, 1086
Novartis Investigative Site
Budapest, Hungary, H-1122
Novartis Investigative Site
Debrecen, Hungary, 4032
Novartis Investigative Site
Pecs, Hungary, 7624
Novartis Investigative Site
Szolnok, Hungary, H-5000
Israel
Novartis Investigative Site
Petach Tikva, Israel, 49100
Novartis Investigative Site
Ramat Gan, Israel, 5266202
Novartis Investigative Site
Zrifin, Israel, 70300
Italy
Novartis Investigative Site
Arezzo, AR, Italy, 52100
Novartis Investigative Site
Cremona, CR, Italy, 26100
Novartis Investigative Site
Meldola, FC, Italy, 47014
Novartis Investigative Site
Milano, MI, Italy, 20133
Novartis Investigative Site
Modena, MO, Italy, 41100
Novartis Investigative Site
Pavia, PV, Italy, 27100
Novartis Investigative Site
Roma, RM, Italy, 00152
Novartis Investigative Site
Candiolo, TO, Italy, 10060
Novartis Investigative Site
Napoli, Italy, 80132
Japan
Novartis Investigative Site
Nagoya-city, Aichi, Japan, 466-8560
Novartis Investigative Site
Toon-city, Ehime, Japan, 791-0295
Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan, 812-8582
Novartis Investigative Site
Hiroshima-city, Hiroshima, Japan, 734-8551
Novartis Investigative Site
Obihiro, Hokkaido, Japan, 080-0016
Novartis Investigative Site
Sapporo-city, Hokkaido, Japan, 060-8648
Novartis Investigative Site
Kobe-city, Hyogo, Japan, 650-0017
Novartis Investigative Site
Kobe-city, Hyogo, Japan, 650-0047
Novartis Investigative Site
Yokohama, Kanagawa, Japan, 241-8515
Novartis Investigative Site
Yokohama-city, Kanagawa, Japan, 236 0037
Novartis Investigative Site
Kyoto-city, Kyoto, Japan, 602-8566
Novartis Investigative Site
Matsumoto, Nagano, Japan, 390-8621
Novartis Investigative Site
Osaka-city, Osaka, Japan, 545-8586
Novartis Investigative Site
OsakaSayama, Osaka, Japan, 589-8511
Novartis Investigative Site
Suita-city, Osaka, Japan, 565-0871
Novartis Investigative Site
Takatsuki-city, Osaka, Japan, 569-8686
Novartis Investigative Site
Hidaka, Saitama, Japan, 350-1298
Novartis Investigative Site
Kitaadachi-gun, Saitama, Japan, 362-0806
Novartis Investigative Site
Bunkyo-ku, Tokyo, Japan, 113-8603
Novartis Investigative Site
Koto, Tokyo, Japan, 135-8550
Novartis Investigative Site
Minato-ku, Tokyo, Japan, 105-8470
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan, 160-8582
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan, 162-8666
Novartis Investigative Site
Chiba, Japan, 260-8717
Novartis Investigative Site
Osaka, Japan, 537-8511
Novartis Investigative Site
Yamagata, Japan, 990-9585
Korea, Republic of
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 05505
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 03722
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 06351
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 110 744
Netherlands
Novartis Investigative Site
Meerssen, KR, Netherlands, 6231
Novartis Investigative Site
Amsterdam, Netherlands, 1081 HV
Novartis Investigative Site
Breda, Netherlands, 4818 CK
Novartis Investigative Site
Dordrecht, Netherlands, 3318AT
Novartis Investigative Site
Maastricht, Netherlands, 6229 HX
Novartis Investigative Site
Rotterdam, Netherlands, 3075 EA
Norway
Novartis Investigative Site
Bergen, Norway, -N5021
Novartis Investigative Site
Ålesund, Norway, NO-6026
Poland
Novartis Investigative Site
Warszawa, Poland, 02-781
Novartis Investigative Site
Warszawa, Poland, 04-141
Saudi Arabia
Novartis Investigative Site
Riyadh, Saudi Arabia, 11211
Slovakia
Novartis Investigative Site
Bratislava, Slovak Republic, Slovakia, 83310
Spain
Novartis Investigative Site
Cordoba, Andalucia, Spain, 14004
Novartis Investigative Site
Malaga, Andalucia, Spain, 29010
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41014
Novartis Investigative Site
Oviedo, Asturias, Spain, 33006
Novartis Investigative Site
Sabadell, Barcelona, Spain, 08208
Novartis Investigative Site
Badalona, Catalunya, Spain, 08916
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08036
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08003
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Hospitalet de LLobregat, Catalunya, Spain, 08907
Novartis Investigative Site
Benidorm, Comunidad Valenciana, Spain, 03501
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46009
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46010
Novartis Investigative Site
Santiago de Compostela, Galicia, Spain, 15706
Novartis Investigative Site
Palma De Mallorca, Islas Baleares, Spain, 07120
Novartis Investigative Site
Las Palmas de Gran Canarias, Las Palmas de Gran Canaria, Spain, 35016
Novartis Investigative Site
Alcorcon, Madrid, Spain, 28922
Novartis Investigative Site
Pamplona, Navarra, Spain, 31008
Novartis Investigative Site
Barcelona, Spain, 08041
Novartis Investigative Site
Madrid, Spain, 28007
Novartis Investigative Site
Madrid, Spain, 28040
Novartis Investigative Site
Madrid, Spain, 28041
Sweden
Novartis Investigative Site
Stockholm, Sweden, SE-171 76
Novartis Investigative Site
Sundsvall, Sweden, 851 86
Novartis Investigative Site
Umeå, Sweden, SE-901 85
Novartis Investigative Site
Uppsala, Sweden, SE-751 85
Switzerland
Novartis Investigative Site
St. Gallen, Switzerland, 9007
Thailand
Novartis Investigative Site
Bangkok, Thailand, 10700
United Kingdom
Novartis Investigative Site
Bristol, Avon, United Kingdom, BS2 8ED
Novartis Investigative Site
Northwood, Middlesex, United Kingdom, HA6 2RN
Novartis Investigative Site
Colchester, United Kingdom, CO3 3NB
Novartis Investigative Site
Leicester, United Kingdom, LE1 5WW
Novartis Investigative Site
London, United Kingdom, NW3 4QG
Novartis Investigative Site
London, United Kingdom, SW17 0QT
Novartis Investigative Site
Manchester, United Kingdom, M20 9BX
Novartis Investigative Site
Southampton, United Kingdom, SO16 6YD
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01223027     History of Changes
Other Study ID Numbers: CTKI258A2302  2009-015459-25 
Study First Received: September 30, 2010
Results First Received: June 29, 2015
Last Updated: November 5, 2015
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Israel: Ministry of Health
Saudi Arabia: Ministry of Health
Brazil: Ministry of Health
Columbia: National Institutes of Health
Argentina: Ministry of Health
Thailand: Food and Drug Administration (KFDA)
Australia: Department of Health and Ageing Therapeutic Goods Administration
Austria: Agency for Health and Food Safety
Belgium: Federal Agency for Medicinal Products and Health Products
Czech Republic: State Institute for Drug Control
France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé
Germany: Federal Institute for Drugs and Medical Devices
Greece: Ministry of Health and Welfare
Hungary: National Institute of Pharmacy
Italy: The Italian Medicines Agency
Japan: Pharmaceuticals and Medical Devices Agency
South Korea: Korea Food and Drug Administration (KFDA)
Netherlands: Medicines Evaluation Board (MEB)
Norway: Norwegian Medicines Agency
Poland: Ministry of Health
Slovakia: State Institute for Drug Control
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Sweden: Medical Products Agency
Switzerland: Swissmedic
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Novartis:
Dovitinib
TKI
Renal cell cancer
RCC
mRCC

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Sorafenib
Niacinamide
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 24, 2016